Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S35-41. doi: 10.1002/cyto.b.20546.

2.

CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.

Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, Salles G, Felman P.

Haematologica. 2010 Apr;95(4):604-12. doi: 10.3324/haematol.2009.011049.

3.

Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.

Challagundla P, Jorgensen JL, Kanagal-Shamanna R, Gurevich I, Pierson DM, Ferrajoli A, Reyes SR, Medeiros LJ, Miranda RN.

Arch Pathol Lab Med. 2014 Jul;138(7):903-9. doi: 10.5858/arpa.2013-0367-OA.

4.

CD5- small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia.

Huang JC, Finn WG, Goolsby CL, Variakojis D, Peterson LC.

Am J Clin Pathol. 1999 Jan;111(1):123-30.

5.

CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients.

Shapiro JL, Miller ML, Pohlman B, Mascha E, Fishleder AJ.

Am J Clin Pathol. 1999 Apr;111(4):477-87.

6.

Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.

Romano C, Sellitto A, Chiurazzi F, Simeone L, De Fanis U, Raia M, Del Vecchio L, Lucivero G.

Int J Hematol. 2015 Jan;101(1):67-74. doi: 10.1007/s12185-014-1703-y.

PMID:
25432435
7.

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.

Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A.

Leukemia. 2002 Aug;16(8):1460-9.

8.

Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.

Alley CL, Wang E, Dunphy CH, Gong JZ, Lu CM, Boswell EL, Burchette J, Lagoo AS.

Arch Pathol Lab Med. 2013 Apr;137(4):503-17. doi: 10.5858/arpa.2011-0696-OA. Review.

PMID:
23544940
9.

The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D.

Leukemia. 1994 Oct;8(10):1640-5.

PMID:
7523797
10.

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma.

Jevremovic D, Dronca RS, Morice WG, McPhail ED, Kurtin PJ, Zent CS, Hanson CA.

Leuk Res. 2010 Sep;34(9):1235-8. doi: 10.1016/j.leukres.2010.03.020.

PMID:
20362334
11.

Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.

Cavalcanti Júnior GB, Sales VS, Cavalcanti e Silva DG, Lopes MC, Paiva Ade S, da Fonseca HE, do Nascimento Júniors FF, Fernandes MZ.

Acta Cir Bras. 2005;20 Suppl 1:101-7.

12.

Deciphering leukemic B-cell chronic lymphoproliferative disorders.

Ugo V, Leporrier N, Salaun V, Letestu R, Radford-Weiss I, Ramond S, Nataf J, Guesnu M, Picard F, Brouzes C, Perrot JY, Valensi F, Levy V, Ajchenbaum-Cymbalista F, Troussard X.

Leuk Lymphoma. 2006 Oct;47(10):2088-95.

PMID:
17071481
13.

Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases.

Khalidi HS, Brynes RK, Browne P, Koo CH, Battifora H, Medeiros LJ.

Mod Pathol. 1998 Oct;11(10):983-8.

PMID:
9796727
14.

[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry].

Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):349-56. doi: 10.7534/j.issn.1009-2137.2014.02.016. Chinese.

PMID:
24763004
15.
16.

MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.

Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED.

Am J Clin Pathol. 2013 Sep;140(3):387-94. doi: 10.1309/AJCP10ZCLFZGYZIP.

17.

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.

Quijano S, López A, Rasillo A, Barrena S, Luz Sánchez M, Flores J, Fernández C, Sayagués JM, Osuna CS, Fernández N, González M, Giraldo P, Giralt M, Pérez MC, Martin-Antoran JM, Gutiérrez O, Perdiguer L, Díaz Mediavilla J, González Silva M, Asensio Del Rio A, Cerveró C, Guerra JL, Butrón R, García Mdel C, Almeida J, Orfao A.

Blood. 2008 May 15;111(10):5130-41. doi: 10.1182/blood-2007-10-119289.

18.

A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias.

Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L.

Am J Hematol. 2008 May;83(5):349-54. doi: 10.1002/ajh.21065.

19.

MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR.

Mod Pathol. 2015 Apr;28(4):564-74. doi: 10.1038/modpathol.2014.120.

20.

Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders.

Vinante F, Vassanelli A, Zanotti R, Nadali G, Krampera M, Vincenzi C, Morosato L, Chilosi M, Pizzolo G.

Int J Clin Lab Res. 1995;25(4):189-94.

PMID:
8788546
Items per page

Supplemental Content

Support Center